Join us as we breakdown the newest research and clinical trial results for metastatic breast cancer from the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Bora Lim, breast oncologist and researcher at MD Anderson, will explain what the findings mean and discuss how these updates could impact patients and their care.
TAKEAWAYS:
Paradigm Shifts: Precision medicine, oral therapies, ADCs transforming metastatic breast cancer
- HR+ Disease: Oral SERDs, ESR1-guided therapy, endocrine effective in visceral disease. Extension of the ER targeted therapy!
- HER2+ Disease: New combinations and drugs such as,T-DXd+pertuzumab and tucatinib, continue to improve outcomes, including for people with brain metastases, expanding effective treatment options. Changes on when to best use T-DXd to help patients get the most benefit.
- TNBC Disease: ADCs first-line for PD-L1 negative, superior PFS/OS, other innovative trials still under investigation
For Healthcare Teams: Stay current, enhance patient education, coordinate genomic testing, monitor for novel toxicities
Patient-Centered Care: Balance efficacy with quality of life, shared decision-making, comprehensive support